Current advances in Hodgkin’s lymphoma  

作　　者：Joseph Vadakara Benjamin Andrick 

机构地区：[1]Department of Hematology and Oncology, Geisinger Medical Center, Danville, PA 17822, USA

出　　处：《Chronic Diseases and Translational Medicine》2019年第1期15-24,共10页慢性疾病与转化医学（英文版）

摘　　要：Hodgkin’s lymphoma is a highly treatable malignancy. It has high cure rates yet there are many patients who relapse or are refractory to treatment. Traditionally, treatment has been with conventional chemotherapy;however, the development of brentuximab vedotin and immune checkpoint inhibitors has revolutionized the care of Hodgkin’s lymphoma. This is a review of the current advances in the management of Hodgkin’s lymphoma and a review of ongoing clinical trials in the field.

关 键 词：Hodgkin’s LYMPHOMA Brentuximab vedotin Nivolumab Pembrolizumab Doxorubicin  bleomycin  vinblastine  and DACARBAZINE (ABVD) 

分 类 号：F[经济管理]